A recent push from health advocates has emerged, urging Canadian provinces and territories to reconsider the age for routine colorectal cancer screenings. The Canadian Cancer Society is advocating for this pivotal change, suggesting that the screening age be lowered from the current threshold of 50 to 45. This initiative comes in response to alarming statistics indicating a significant rise in colorectal cancer diagnoses among younger adults.
A Personal Journey with Colorectal Cancer
Michael Groves, a 54-year-old Ottawa resident, discovered he had Stage 3 colorectal cancer after experiencing abdominal pain in January 2021. Initially dismissed as appendicitis and later resolved, Groves returned home only to notice blood in his stool days later. His family doctor, taking the precautionary route, scheduled a colonoscopy for April. “The idea that it could be colon cancer never crossed my mind,” Groves recounted.
Upon waking from the procedure, Groves received the life-altering news that a five-centimetre tumour had been detected, and the cancer had already spread to two lymph nodes. “The shock was just, like, wow, just devastating,” he reflected, noting he had felt perfectly healthy prior to his diagnosis. “I had just completed a 5K run and was feeling great.”
Following surgery to remove a portion of his colon, Groves endured a challenging six-month chemotherapy regimen, resulting in a significant impact on his work life and well-being. He believes that had he undergone routine screenings in his 40s, his cancer might have been detected at an earlier, more treatable stage.
Rising Cases Among Younger Adults
Groves’ experience is increasingly common, as the Canadian Cancer Society reports a troubling trend: individuals under the age of 50 are now 2 to 2.5 times more likely to be diagnosed with colorectal cancer compared to previous generations. Brandon Purcell, the society’s advocacy manager for prevention and early detection, stressed the urgency for governmental action. “This growth is concerning for us, and we think it’s time for governments to react so we can catch more of these cancers early,” he stated.
Currently, Canadians aged 50 and older are offered a fecal immunochemical test (FIT) to detect potential signs of cancer by collecting stool samples at home. If blood is found in the sample, further investigation through a colonoscopy is initiated. However, many younger individuals without overt symptoms are left unmonitored.
The Case for Earlier Screening
Health experts argue that expanding screening to include those aged 45 and older could significantly enhance early detection rates. According to the Canadian Cancer Society, the survival rate for colorectal cancer can exceed 90% when identified in its early stages. In stark contrast, this rate plummets to less than 15% in advanced cases.
Colonoscopy procedures are not only crucial for detecting cancerous tumours but also for identifying and removing precancerous polyps, which can take years to develop into cancer. Barry Stein, CEO of Colorectal Cancer Canada, echoed the call for screenings to start at 45, citing a recent study published in the Journal of the Canadian Association of Gastroenterology. The study posits that screening at this younger age could potentially avert 15,070 colorectal cancer cases and 6,100 deaths over the next 45 years.
Financial Implications of Screening
The study also highlighted the economic benefits of lowering the screening age, estimating a cost saving of approximately $233 million in cancer treatment expenses, even when factoring in the costs of the additional tests and procedures. This presents a compelling argument not just from a health perspective but also from a fiscal standpoint.
Why it Matters
The call for a change in colorectal cancer screening guidelines reflects a broader public health concern. As more individuals are diagnosed with this disease at younger ages, the need for proactive measures becomes ever more pressing. By adopting a lower screening age, Canada could potentially save lives, improve health outcomes, and reduce the financial burden of late-stage cancer treatments. The stakes are high, and the time for action is now.
